TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| 3-D Vision - American Optometric Assoc. - Video 3-D TV and Movies Look to Attract Viewers But Not Everyone Can ‘See’ What All the Hype is About feedproxy.google.com |
Glaxo Rival Paid Fees to Doctor Who Voted Against Avandia A doctor who voted against the diabetes drug Avandia at an FDA advisory panel last week said he earlier served a paid speaker for the maker of a rival drug. online.wsj.com |
ImmunoGen, Inc. F4Q10 (Qtr End 06/30/10) Earnings Call Transcript ImmunoGen, Inc. (IMGN)F4Q10 (Qtr End 06/30/10) Earnings Call August 04, 2010 04:30 pm ETComplete Story » seekingalpha.com |
Biodel: Upside from Potential Linjeta Approval Rockford Coscia submits:I wanted to weigh in on the Biodel (BIOD) PDUFA for their rapid-acting insulin formulation, Linjeta. Many investigations have taken place here, here, and here (and my first article offered a play that has returned over 50% since July here), but I thought it would be worthwhile to provide a summary of what’s at stake. Linjeta, to provide a little background, is a new formulation of rapid-acting prandial (meal-time) insulin. It is basically regular insulin that has been treated with EDTA to break the hexameric insulin into three dimers. The remaining dimers are treated with citric acid in order to break the dimers into monomers. What results is an insulin that goes to work faster (it doesn’t have to break down in the body from hexamer to monomer) and is supposed to more closely mimic the body’s natural insulin response.Complete Story » seekingalpha.com |
Zimmer Holdings: Nothing to Get Excited About Margin of Safety Investing submits: Zimmer Holdings (ZMH) is a leader in knee and hip implants and plays in a number of other orthopedic niches. The company was added to the idea pipeline as Morningstar rates it a 5-star wide moat company. ZMH’s stock is currently trading at $51-52. 1- Business Performance Risk (=) and intrinsic returns (=)Complete Story » seekingalpha.com |